Investors
Medical Professionals
Patients
Careers
Quick Links
Follow Us
From our collaborator Regeneron, the 7th Alnylam-discovered approval in the U.S.
Replay of the online event is now available
Alnylam's 2025 report details our progress against our corporate responsibility goals
CEO Yvonne Greenstreet reflects on a transformational year.
Past Events ›
Download
Explore Capella ›
Q3 2026 Earnings Presentation VIEW PDF ›
Latest Form 10-K VIEW PDF ›
Latest Form10-Q VIEW PDF ›
SEC Filings VIEW All ›
2026 Proxy Statement LEARN MORE ›
Discover Our Commitment to Patients, Employees, and Our Communities
Corporate Responsibility ›
Learn More ›